Alzheimer’s research in the news
From local news to global conversations and groundbreaking research, health care is constantly evolving and highly covered in the media. Here, we share the latest news and trends – and how they drive our work to best serve our communities and members.
A nationwide clinical trial being administered in Massachusetts is testing if an increased lab-made version of thiamine, or vitamin B1, can help slow cognitive decline in people with early Alzheimer’s disease.
The ongoing BenfoTeam clinical research trial is designed for people who are aged 50 to 89 and are experiencing significant memory concerns, or who have already been diagnosed with mild cognitive impairment or mild Alzheimer’s disease. Participants will either be given the benfotiamine or a placebo pill and will be followed for 18 months. Past research on a smaller scale has shown encouraging results.
Nearly 7 million Americans are currently living with Alzheimer’s and it’s predicated that number will rise to nearly 13 million by 2050. Symptoms can vary and may include memory loss, language difficulties, low energy and changes in personality. In its advanced stages, Alzheimer’s disease can cause complications that lead to death. There is currently no cure for Alzheimer’s.
Every fall, Point32Health colleagues join the Walk to End Alzheimer’s at locations across New England to support the Alzheimer’s Association. This year, 1,600 colleagues, friends and family members participated, raising more than $80,000. With a match from the Point32Health Foundation, the Alzheimer’s Association will receive more than $160,000 to support its 24/7 hotline, advocacy for those living with Alzheimer’s, caregiver programs and research to find a cure.
Point32Health Foundation, the philanthropic arm of Harvard Pilgrim Health Care and Tufts Health Plan, also provides grants to destigmatize dementia, increase support for patients and families, and expand education and outreach. Learn more about the Point32Health Foundation’s work to support healthy aging: